Target the Gene
Silence the Disease

Pipeline

Drug(indication)
Indication
Pre-clinical
Pre-IND
Phase 1
Phase 2
Phase 3
  • ARO-AAT (Alpha-1 Antitrypsin Deficiency)
    Alpha-1 Antitrypsin Deficiency
    CTA planned Q1 2018
  • ARO-HBV (Hepatitis B)
    Hepatitis B
    CTA planned Q2 2018
  • ARO-APOC3 (Hypertriglyceridemia)
    Hypertriglyceridemia
    CTA planned Q4 2018
  • ARO-ANG3 (Hypertriglyceridemia)
    Hypertriglyceridemia
    CTA planned Q4 2018
  • ARO-Lung1 (Undisclosed)
    Undisclosed
    CTA planned Q4 2018
  • ARO-HIF2 (Renal Cell Carcinoma)
    Renal Cell Carcinoma
    CTA planned 2019
  • ARO-F12 (Thrombosis / Hereditary Angiodema)
    Thrombosis / Hereditary Angiodema
    Available for partnering
  • ARO-LPA (Cardiovascular Disease)
    Cardiovascular Disease
    Partnered with Amgen
  • ARO-AMG1 (Cardiovascular Disease)
    Cardiovascular Disease
    Partnered with Amgen
*Guidance accurate as of 9/14/17

Science

Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.

Learn More

About Arrowhead

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.

 

 

Learn More